海岛地区肺腺癌microRNA-135b与表皮生长因子受体基因突变的相关性

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1615 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the relationship between EGFR mutations and miR-135b in lung adenocarcinoma of Zhoushan Archipelago and find new indicator for the guidance of EGFR-TKIs. Methods: MiR-135b quantification was retrospectively detected in 70 paraffin-embedded lung adenocarcinoma tissue samples and the corresponding para-carcinoma tissue using Taqman-based quantitative RT-PCR assays (qRT-PCR). The EGFR gene exons 19 and 21 of tumor tissue were amplified by PCR, followed by direct sequencing in 70 paraffin-embedded lung adenocarcinoma tissue. Results: MiR-135b was markedly up-regulated in lung adenocarcinomas in comparison to the corresponding para-carcinoma tissue (P<0.01) and miR-135b had a higher level in the group of invasive lung adenocarcinoma (IAC) compared to the group of noninvasive lung adenocarcinoma (adenocarcinoma in situ/minimally invasive adenocarcinoma, AIS/MIA) (P<0.01); EGFR mutations were detected in 24 cases of 70 (34.3%) patients with lung adenocarcinoma. The mutation rate in IAC (53.3%) was higher than that in AIS/MIA (20%). Patients harbouring EGFR mutations had higher miR-135b expression level, which indicated that miR-135b was positive correlation with EGFR mutations. Conclusion: EGFR mutations and miR-135b may be positive correlation with the invasion of lung adenocarcinoma and both of them can be used to assess the progress of lung adenocarcinoma. MiR-135b can be the biological marker for effectiveness evaluation of EGFR TKIs and is expected to become the new target for improving EGFR TKIs resistance.

Key words： epidermal growth factor receptor microRNA-135b lung neoplasms adenocarcinoma invasion epidermal growth factor receptor tyrosine kinase inhibitors

Received: 26 April 2016

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Xiaoling
	ZHA Yao
	MA Haijie
	ZHU Wangyu
	ZHANG Yongkui
	CHEN Xiaoming.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2017/V47/I4/248

[1] SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[2] TRAVIS W D, BRAMBILLA E, RIELY G J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials[J]. J Clin Oncol, 2013, 31(8): 992-1001.
[3] SARDENBERG R A, MELLO E S, YOUNES R N. The lung adenocarcinoma guidelines: what to be considered by surgeons [J]. J Thorac Dis, 2014, 6(5): S561-S567.
[4] KAZANDJIAN D, BLUMENTHAL G M, YUAN W, et al.FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer[J]. Clin Cancer Res, 2016, 22(6): 1307-1312.
[5] SIEGELIN M D, BORCZUK A C. Epidermal growth factor receptor mutations in lung adenocarcinoma[J]. Lab Invest, 2014, 94(2): 129-137.
[6] 王明, 孙震宇, 黄礼年. MiRNAs与EGFR-TKIs继发性耐药机制的研究进展[J]. 中国肺癌杂志, 2015, 18(12): 758-763.
[7] VOLINIA S, CALIN G A, LIU C G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci U S A, 2006, 103(7): 2257-2261.
[8] CROCE C M. Causes and consequences of microRNA dysregulation in cancer[J]. Nat Rev Genet, 2009, 10(10): 704-714.
[9] NAGEL R, LE SAGE C, DIOSDADO B, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer[J]. Cancer Res, 2008, 68(14): 5795-5802.
[10] LI Y, XU D, BAO C, et al. MicroRNA-135b, a HSF1 target, promotes tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma[J]. Oncotarget,2015, 6(4): 2421-2433.
[11] ZHANG L, SUN Z J, BIAN Y, et al. MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma[J]. Cancer Lett, 2013, 331(2): 230-238.
[12] ARIGONI M, BARUTELLO G, RICCARDO F, et al. miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2[J].Am J Pathol, 2013, 182(6): 2058-2070.
[13] RIELY G J, PAO W, PHAM D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib[J]. Clin Cancer Res, 2006, 12(3): 839-844.
[14] SOH J, TOYOOKA S, ICHIHARA S, et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung[J]. J Thorac Oncol,2008, 3(4): 340-347.
[15] YOSHIDA Y, SHIBATA T, KOKUBU A, et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the
lung[J]. Lung cancer, 2005, 50(1): 1-8.
[16] HAYES D N, MCLEOD H L. EGFR regulation by microRNA in lung cancer: a rose by any other name is an increasingly complicated rose[J]. Ann Oncol, 2008, 19(6): 1036-1037.
[17] ZHEN Q, LIU J, GAO L, et al. MicroRNA-200a targets EGFR and c-Met to inhibit migration, invasion, and gefitinib resistance in non-small cell lung cancer[J]. Cytogenet Genome Res, 2015, 146(1): 1-8.
[18] SHEN Y, TANG D, YAO R, et al. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation[J]. Med Oncol, 2013, 30(4): 1-8.
[19] MATSUYAMA H, SUZUKI H I, NISHIMOR I, et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma[J]. Blood, 2011, 118(26): 6881-6892.
[20] DOBI E, MONNIEN F, KIM S, et al. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer [J]. Clin Colorectal Cancer, 2013, 12(1): 28-36.
[21] WEICKHARD A J, PRICE T J, CHONG G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy refractory, advanced colorectal cancer [J]. J Clin Oncol, 2012, 30(13): 1505-1512.
[22] KHATRI R, SUBRMANIAN S. MicroRNA-135b and its circuitry networks as potential therapeutic targets in colon cancer[J]. Front Oncol, 2013, 3(49): 1-4.
[23] PAK M G, LEE C H, LEE W J, et al. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status[J]. Diagn Pathol, 2015, 10(1): 1-9.
[24] 蒲桂梅, 叶君如, 卢瑶, 等. 非小细胞肺癌患者EGFR基因突变与血清肿瘤标志物之间关系探讨[J]. 温州医科大学学报, 2014, 44(9): 667-671.

[1]	. [J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2022, 52(9): 764-766,770.